BCR and B-cell chronic lymphocytic leukemia: We also found that CLL cases with unmutated IGHV are more sensitive to cerdulatinib, which is consistent with our previous results that this subtype of CLL has higher intrinsic BCR activity rendering them more vulnerable to BCR-targeted therapy [9].